S&P Biotech ETF (CURE) – Global X ETFs Australia
Australia
Search

CURE

S&P Biotech ETF

Invest in CURE Request Research
Overview Performance Holdings & Characteristics Research Documents Announcements FAQs

Reasons to Consider CURE

High Growth Potential

Genomic sequencing and genetic medicines & therapeutics are helping transform health care in key areas with growing demand, including drug development, precision medicine, and more.

Risk Controls

Limit company-specific risks, such as risk of testing failures or higher than anticipated development costs, by using an equal weighting across many biotechnology companies.

Targeted Exposure

CURE provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

Product Information As of 12 Sep 2024

Inception Date 8 Nov 2018
Management Costs (% p.a.) 0.45
Currency Hedged No
Domicile Australia
Legal Form Managed Investment Scheme
SMSF Eligible Yes

NAV Information As of 12 Sep 2024

NAV/Unit (A$) 50.51590000
Currency (NAV) AUD
Shares Outstanding 824,012
AUM (A$) 41,625,721.47
NAV History File View

Product Summary

The Global X S&P Biotech ETF (CURE) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

Product Objective

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

Trading Details

Ticker CURE
Bloomberg Code CURE AU Equity
ISIN AU0000028110
Trading Hours 10:00AM – 4:00PM

Management & Administration

Issuer Global X Management (AUS) Limited
Custodian The Hongkong and Shanghai Banking Corporation Limited, Sydney Branch
Registrar Computershare Investor Services Pty Limited

Benchmark Information

Benchmark S&P Biotechnology Select Industry Index
Provider S&P Indices
Ticker SPSIBIN

Distributions As of 30 Aug 2024

12-Month Yield 0.00%
12-Month Franking Level 0.00%
Distribution Frequency Annually
Distribution History View

Performance Table As of 12 Sep 2024

Total Return (Fund) Total Return (Benchmark) Tracking Difference Tracking Error
1 Month 1.99% 2.06% -0.07% 0.02%
3 Months 5.62% 5.81% -0.18% 0.09%
1 Year 19.72% 20.35% -0.64% 0.42%
3 Year p.a. -6.17% -5.84% -0.33% 1.00%
5 Year p.a. 3.98% 4.42% -0.44% 0.86%
10 Year p.a. -- -- -- --
Since Inception p.a. 4.07% 4.51% -0.44% 0.82%

Top Holdings As of 13 Sep 2024

Full Holdings (.xlsx)
Net Assets (%) Name SEDOL Market Price (Local) Shares Held Market Value (A$)
4.13 EXACT SCIENCES 2719951 67.39 17,068 1,718,916
3.25 GILEAD SCIENCES 2369174 82.39 10,987 1,352,789
3.04 UNITED THERAPEUT 2430412 341.11 2,481 1,264,730
2.95 ABBVIE INC B92SR70 194.02 4,240 1,229,388
2.94 ALNYLAM PHARMACE B00FWN1 261.73 3,128 1,223,480
2.92 VIKING THERAPEUT BQQG1V1 62.81 12,941 1,214,712
2.88 REGENERON PHARM 2730190 1,164.46 690 1,200,743
2.85 NATERA INC BYQRG48 125.12 6,336 1,184,727
2.84 AMGEN INC 2023607 330.06 2,394 1,180,847
2.59 BIOMARIN PHARMAC 2437071 84.38 8,559 1,079,292
2.56 VERTEX PHARM 2931034 478.65 1,487 1,063,667
2.50 SAREPTA THERAPEU B8DPDT7 125.34 5,563 1,042,018
2.48 INCYTE CORP 2471950 63.36 10,906 1,032,660
2.19 BIOGEN INC 2455965 197.89 3,085 912,338
2.02 NEUROCRINE BIOSC 2623911 121.28 4,647 842,245
1.96 CYTOKINETICS INC BBBSBJ5 54.06 10,113 817,020
1.50 VAXCYTE INC BKPVGH6 114.13 3,651 622,713
1.39 ROIVANT SCIENCES BMW4NZ9 12.12 31,991 579,438
1.28 MODERNA INC BGSXTS3 69.68 5,105 531,594
1.27 EXELIXIS INC 2576941 26.31 13,472 529,699
1.23 APELLIS PHARMACE BYTQ6X1 36.78 9,332 512,936
1.18 MADRIGAL PHARMAC BD59BS7 234.76 1,405 492,921
1.16 CRISPR THERAPEUT BDHF4K6 45.89 7,040 482,800
1.15 INSMED INC 2614487 73.91 4,327 477,933
1.13 KRYSTAL BIOTECH BD6JX35 195.64 1,612 471,302
1.11 BLUEPRINT MEDICI BWY52P3 84.10 3,662 460,247
1.10 HALOZYME THERAPE 2975098 60.54 5,051 456,979
1.08 TG THERAPEUTICS B828K63 23.19 12,994 450,319
1.08 REVOLUTION MEDIC BL71K91 41.97 7,159 449,022
1.06 ALKERMES PLC B3P6D26 26.56 11,125 441,575
1.01 BRIDGEBIO PHARMA BK1KWG8 26.95 10,474 421,840
1.01 ULTRAGENYX PHARM BJ62Z18 57.83 4,865 420,448
0.97 BIOHAVEN LTD BPLZ7S5 35.75 7,545 403,099
0.96 IONIS PHARMACEUT BDJ0LS6 41.02 6,512 399,196
0.89 ARCELLX INC BPCJ1Q2 74.77 3,309 369,744
0.88 IOVANCE BIOTHERA BF0DMK7 9.46 25,978 367,260
0.80 CRINETICS PHARMA BDD19F8 51.23 4,326 331,198
0.78 SPRINGWORKS THER BGMGM89 35.99 6,011 323,300
0.73 NUVALENT INC-A BMVBZD3 81.68 2,495 304,553
0.71 AMICUS THERAPEUT B19FQ48 11.28 17,611 296,872
0.69 CELLDEX THERAPEU BJLV8T9 41.75 4,608 287,505
0.68 ADMA BIOLOGICS I B9NSBM2 17.65 10,793 284,684
0.67 ACADIA PHARMACEU 2713317 15.95 11,765 280,433
0.67 DYNE THERAPEUTIC BN15WD1 33.07 5,606 277,054
0.64 TWIST BIOSCIENCE BGKG6G7 44.57 3,975 264,762
0.63 SUMMIT THERAPEUT BMTVQS7 27.41 6,358 260,439
0.63 AVIDITY BIOSCIEN BMWHPY1 41.31 4,216 260,275
0.60 VERA THERAPEUTIC BL55460 35.66 4,695 250,204
0.60 IDEAYA BIOSCIENC BK0VHF6 36.11 4,634 250,069
0.60 INTELLIA THERAPE BYZM6C2 20.67 8,042 248,417
0.60 GERON CORP 2370381 4.45 37,308 248,107
0.58 DENALI THERAPEUT BD2B4V0 27.96 5,805 242,558
0.56 KYMERA THERAPEUT BMPRZV5 44.72 3,502 234,042
0.56 IMMUNOVANT INC BJRFSB7 28.86 5,426 234,020
0.56 BEAM THERAPEUTIC BK6L288 24.40 6,373 232,386
0.55 ARDELYX INC BN89V40 6.22 24,630 228,945
0.52 CATALYST PHARMAC B1G7Q03 20.29 7,109 215,559
0.51 APOGEE THERAPEUT BM9HHL5 49.19 2,868 210,830
0.50 BIOCRYST PHARM 2100362 7.75 17,848 206,713
0.49 JANUX THERAPEUTI BMFX8Y7 46.53 2,960 205,827
0.49 RHYTHM PHARMACEU BF2YWG4 49.31 2,781 204,933
0.47 AGIOS PHARMACEUT BCBVTX1 44.92 2,945 197,698
0.47 PROTAGONIST THER BDCBCD8 45.65 2,884 196,749
0.47 DYNAVAX TECHNOLO BRJZSK0 10.97 11,944 195,809
0.46 VERACYTE INC BFTWZY0 30.42 4,219 191,799
0.45 PTC THERAPEUTICS B17VCN9 32.70 3,850 188,142
0.45 KEROS THERAPEUTI BM7V485 56.40 2,206 185,935
0.45 NURIX THERAPEUTI BMVLGP2 23.57 5,262 185,348
0.44 SYNDAX PHARMACEU BN7Q7R7 17.99 6,818 183,301
0.43 NOVAVAX INC BJDQXG4 11.92 10,036 178,778
0.43 AKERO THERAPEUTI BK7Y2V9 25.70 4,637 178,093
0.41 VIRIDIAN THERAPE BMDH2B6 20.70 5,556 171,874
0.41 ARROWHEAD PHARMA BYQBFJ8 20.24 5,616 169,827
0.40 VERICEL CORP BSBMN89 44.27 2,534 167,646
0.39 MIRUM PHARMACEUT BJDX8Y8 41.13 2,639 162,209
0.38 ARCUTIS BIOTHERA BKX9VD3 10.52 9,944 156,334
0.37 SOLENO THERAPEUT BL6JK96 49.61 2,067 153,245
0.36 CAREDX INC BP3YM74 29.43 3,427 150,723
0.36 RECURSION PHAR-A BM9FJ13 6.50 15,248 148,116
0.34 KURA ONCOLOGY IN BYZD465 19.89 4,774 141,904
0.34 MYRIAD GENETICS 2614153 26.39 3,581 141,228
0.33 PRAXIS PRECISION BQ721R4 58.70 1,585 139,041
0.32 TRAVERE THERAPEU BLFGJD5 12.60 7,030 132,374
0.31 ROCKET PHARMACEU BDFKQ07 18.94 4,509 127,625
0.30 MANNKIND CORP BF081J4 6.20 13,427 124,408
0.28 AVID BIOSERVICES BFMZ4W7 11.16 7,063 117,796
0.28 DAY ONE BIOPHARM BLB0YH0 13.67 5,735 117,160
0.28 PROTHENA CORP PL B91XRN2 20.72 3,718 115,127
0.27 XENCOR INC BGCYWN8 20.82 3,660 113,878
0.26 SPYRE THERAPEUTI BQBBDY8 28.44 2,572 109,314
0.26 ANAPTYSBIO INC BDRW1L7 38.30 1,904 108,979
0.26 COGENT BIOSCIENC BLR6XK8 10.27 7,050 108,202
0.25 CULLINAN THERAPE BM90J52 17.62 4,010 105,591
0.24 CG ONCOLOGY INC BRBCSP4 34.83 1,953 101,656
0.24 IRONWOOD PHARMAC B3MZ6K5 4.53 14,729 99,712
0.23 IMMUNOME INC BM8FWX7 14.71 4,447 97,759
0.23 ARCUS BIOSCIENCE BDZT9Y9 17.39 3,694 96,000
0.22 ALTIMMUNE INC BFY7DC4 7.10 8,545 90,667
0.21 ARCTURUS THERAPE BKC9SX3 19.91 2,990 88,965
0.21 SANA BIOTECHNOLO BMFJJ97 4.53 13,046 88,319
0.21 4D MOLECULAR THE BKLXFX5 15.91 3,685 87,616
0.21 IMMUNITYBIO INC BNSP0B8 3.49 16,695 87,074
0.21 KINIKSA PHARMACE BRXB0C0 24.49 2,337 85,531
0.20 RELAY THERAPEUTI BN2R582 7.62 7,479 85,168
0.17 REGENXBIO INC BZ0G875 12.18 3,979 72,427
0.17 OLEMA PHARMACEUT BMZ4LN0 11.85 3,934 69,667
0.17 CORBUS PHARMACEU BNHTR76 51.58 895 68,989
0.16 C4 THERAPEUTICS BKX9NQ0 6.41 7,163 68,617
0.16 ANAVEX LIFE SCIE BYTYP72 5.21 8,650 67,349
0.16 ASTRIA THERAPEUT BMYRFN8 10.62 4,235 67,213
0.16 89BIO INC BK1K484 8.09 5,535 66,918
0.16 DISC MEDICINE IN BMGJZJ8 48.27 925 66,726
0.16 VIR BIOTECHNOLOG BK4PZ38 7.86 5,624 66,061
0.15 SCHOLAR ROCK HOL BFZQ0L8 8.26 5,129 63,312
0.15 STOKE THERAPEUTI BJQ05Z6 13.71 3,081 63,126
0.15 ALLOGENE THERAPE BFZNYB7 2.66 15,704 62,426
0.15 ARS PHARMACEUTIC BMCR7V2 12.63 3,290 62,098
0.15 ORIC PHARMACEUTI BKVDFF7 9.06 4,481 60,671
0.13 OCUGEN INC BK71M09 1.20 30,741 55,128
0.13 FATE THERAPEUTIC BCZS820 3.74 9,442 52,773
0.12 SAGE THERAPEUTIC BP4GNK9 7.36 4,640 51,035
0.12 CARGO THERAPEUTI BQHN2F2 22.00 1,523 50,072
0.11 MIMEDX GROUP INC B1Z3TW5 6.15 5,202 47,810
0.11 VERVE THERAPEUTI BNKGXX2 5.65 5,619 47,444
0.11 EDITAS MEDICINE BZ8FPH3 3.75 8,090 45,337
0.10 TANGO THERAPEUTI BP2P6L0 10.00 2,744 41,007
0.08 SCILEX HOLDING C BLKFRT9 1.06 21,910 34,708
0.08 ITEOS THERAPEUTI BMWXFT4 16.90 1,355 34,222
0.08 HUMACYTE INC BMYTJP4 5.62 3,927 32,982
0.08 SAVARA INC BYXGN81 4.24 5,107 32,360
0.08 ALECTOR INC BJ4LDC4 5.61 3,789 31,766
0.08 VOYAGER THERAPEU BY7RB53 6.22 3,360 31,232
0.07 ZENTALIS PHARMAC BMQ5T49 3.15 6,309 29,699
0.06 HERON THERAPEUTI BJ0XLZ3 1.84 9,697 26,664
0.06 CABALETTA BIO IN BK5MWR1 4.03 3,900 23,488
Holdings are subject to change.

Sector Breakdown As of 13 Sep 2024

Sector Weight (%)
Health Care 99.8
Other/Cash 0.2

Country Breakdown As of 13 Sep 2024

Country Weight (%)
United States 97.3
Ireland 1.3
Switzerland 1.2
Other/Cash 0.2

Research

Investing in Pharma: The Drug Lifecycle

Read More

Charting Disruption: Medical Breakthroughs

Read More

AI Applications in Healthcare: From Drug Discovery to Patient Care

Read More

Documents

FAQs

  • What is biotechnology?

    Biotechnology includes companies primarily engaged in the research, development, manufacturing and/or marketing of products based on genetic analysis and genetic engineering. It includes companies specialising in protein-based therapeutics to treat human diseases. It excludes companies manufacturing products using biotechnology but without a healthcare application. Biotechnology is a sub-industry of the healthcare sector.

  • How does biotechnology differ from healthcare?

    Biotechnology is a sub-industry within the Healthcare sector.

    The Healthcare sector refers to all those industries involved in providing goods and services to manage the health needs of individuals and populations. There are two main groupings within the healthcare sector according to the Global Industry Classification Standards (GICS) including:

    Healthcare equipment and services

    Pharmaceuticals, biotechnology, and Life Sciences.

  • How are companies in CURE weighted?

    Companies in CURE are equally weighted (subject to liquidity constraints), meaning each holding makes up the same portion of the portfolio at each quarterly rebalance and therefore contributes equally to overall performance.

    The choice of an equal weighting scheme provides investors exposure to the overall sector and allows all stocks to contribute equally to returns. Large-cap stocks do not dominate as they do where holdings are weighted by market capitalisation.

  • Why use CURE for biotechnology exposure?

    While biotechnology can be a lucrative space, it can also be high risk. The drug development process is very lengthy with high failure rates and it is an area that is sensitive to government policy. Using an ETF like CURE not only spreads the risk over many biotechnology companies but reduces the single stock risk further by using an equal weight method.

    CURE enables investors to access the growth in the U.S. biotechnology sector, without having to pick individual winners.

  • How can you use CURE in a portfolio?

    CURE may be used as a tool for expressing long-term strategic or short-term tactical views on the biotechnology sub-industry.

    CURE can also aid portfolio diversification via investment in a sector that is underrepresented in the Australian market.

Global X Management (AUS) Limited (“Global X”) (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at www.globalxetfs.com.au. The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Back to Top